Plain-English translation of NCT07377643 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is comparing a new drug called —given either by itself or combined with a second medication—against the current standard treatment for advanced HER2-positive breast cancer. The goal is to see if the new medication works better, is easier to tolerate, or offers other benefits compared to what doctors typically use today. About 540 patients will be enrolled across multiple hospitals.
HER2-positive breast cancer is an aggressive form of the disease, and while current treatments help many people, doctors are always looking for better options with fewer side effects or improved outcomes. This trial will test whether the new treatment can improve how well patients respond and how well they tolerate the medication.
You likely qualify if…
You likely don't qualify if…
If enrolled, you will be randomly assigned to one of three groups: receiving the new medication with a second drug, the new medication alone, or the current standard treatment. You will receive the medication (likely by infusion) on a regular schedule at the hospital or clinic, with frequent follow-up visits for blood tests, imaging scans, and heart function checks. Your doctor will monitor you closely for side effects and how well the treatment is working, with the study lasting as long as your cancer responds to treatment or until you and your doctor decide to stop.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China